MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided…Read More
Phio Pharmaceuticals Corp Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
